BioLineRx Ltd.

Foreign Filer Report • Jan 14, 2020

BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe false

������� �� ��� ��"�	2 380
BIOLINE RX LTD
Corporation no: 513398750	9253
- - -

	Israel Securities Authority			Tel Aviv Stock Exchange		C002 ( Public )		Reported via MAGNA:	14/01/2020
	www.isa.gov.il			www.tase.co.il				Reference:	2020-02-005185	Time of broadcast: 13:52 13:43:52

---

Immediate ReportRegulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000

	The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report onBioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe

6-K_BL-8040_140120_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
- - -
Stock Exchange/Market: NASDAQ CM	Date of revision of form structure: 31/12/2019
Address: HaMa'ayan 2 , Modi'in 7177871   , Israel Tel: 08-6429100 , Fax: 08-6429101
E-mail address: info@BioLineRx.com   Company site: www.biolinerx.com
Previous names of reporting entity:
Name of the Signatory: Kotler Norman Harold Position of Signatory in the reporting corporation: General Counsel & Company Secretary Name of Employer Company:
Address: HaMa'ayan 2 , Modi'in 7177871 Telephone: 08-6429100 Facsimile: 08-6429101 E-mail: normank@biolinerx.com 1
Israel